Tags : Host Factors

COVID-19 Pharma

Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi

Shots: The collaboration will evaluate RNAi therapeutics targeting three host factors required for SARS-CoV-2 infection, including ACE2 and TMPRSS2. The third target is expected to emerge from Vir’s ongoing genomics efforts for identifying novel host factors relevant to COVID-19 Under the amended collaboration, Vir will be responsible for the development of selected DCs and the […]Read More